Alomide®
lodoxamide 0.1% · ophthalmic solution
Allergy
Approved uses
Vernal keratoconjunctivitis, including vernal conjunctivitis and vernal keratitis
1 or 2 drops in each affected eye QID for up to 3 months
Effect builds over weeks of continuous QID dosing rather than after a single drop.
OFF-LABELNot in the FDA label for this product
Superior limbic keratoconjunctivitis
1 drop BID long term; the series added fluorometholone acetate 0.1% for 7 to 14 days at presentation and at relapse for moderate or severe inflammation
Uncontrolled series · n=34
Prospective, non-comparative series of 67 eyes in 34 patients on a mean 15.3 months of therapy: 82.0% of eyes reached control of inflammation at a mean of 2.2 months, signs improved significantly by month 3 (p<0.05), 35.8% reached remission, 18.0% relapsed on therapy, and 7.4% failed. No control arm and concomitant pulsed steroid, so the effect cannot be attributed to lodoxamide alone; it supports it as a steroid-sparing maintenance option, not as proven monotherapy.
Seasonal and perennial allergic conjunctivitis
1 drop in each eye QID; the trial ran 14 days
RCT · n=93 · no placebo arm
Randomized, double-masked, seven-center trial in 93 patients with seasonal or perennial allergic conjunctivitis, QID against levocabastine 0.05% BID: both arms produced statistically and clinically significant reductions from baseline in symptom and sign scores by days 7 and 14 with no difference between groups. After the first instillation, however, signs were relieved faster in the levocabastine arm (p<0.001), which is the practical argument for reaching for an antihistamine when a patient needs same-day relief. No placebo arm.
Contraindications
Hypersensitivity to any component of the product.
Ophthalmic solution, 0.1% (1.78 mg/mL lodoxamide tromethamine, equivalent to 1 mg/mL base), 10 mL plastic ophthalmic dispenser
Mast cell stabilizer that inhibits the in vivo Type I immediate hypersensitivity reaction. In vitro, lodoxamide stabilized rodent mast cells and prevented antigen-stimulated release of histamine; it also prevents release of other mast cell inflammatory mediators (the peptido-leukotrienes) and inhibits eosinophil chemotaxis. Its precise mechanism of action is unknown, but it has been reported to prevent calcium influx into mast cells upon antigen stimulation. It has no intrinsic vasoconstrictor, antihistaminic, cyclooxygenase inhibition, or other anti-inflammatory activity.
Warnings & Precautions
- Topical ophthalmic use only: Not for injection.
- Soft contact lenses: Should not be worn during treatment; preserved with benzalkonium chloride 0.007%.
- Transient burning or stinging: Patients may experience transient burning or stinging upon instillation; should these symptoms persist, the patient should be advised to contact the prescribing physician.
- Tip contamination: Keep the dropper tip off any surface.
Common Side Effects
The most frequently reported ocular adverse experiences were transient burning, stinging, or discomfort upon instillation, in approximately 15% of subjects. Other ocular events in 1% to 5% of subjects included ocular itching, blurred vision, dry eye, tearing or discharge, hyperemia, crystalline deposits, and foreign body sensation. Corneal erosion or ulcer, keratopathy or keratitis, corneal abrasion, epitheliopathy, and anterior chamber cells occurred in less than 1% of subjects. Nonocular events were headache (1.5%) and, at less than 1%, heat sensation, dizziness, somnolence, nausea, stomach discomfort, sneezing, dry nose, and rash.
Pregnancy: No adequate and well-controlled studies in pregnant women; oral doses in rats and rabbits more than 5000 times the proposed human clinical dose produced no evidence of developmental toxicity. Use only if clearly needed.
Lactation: Excretion in human milk is unknown; use caution in nursing women.
Safety and effectiveness in pediatric patients below the age of 2 years have not been established. The labeled dose is for adults and children greater than 2 years of age.